PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Other Long-Term Liabilities: MAD171.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAS:PRO PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
90 GF Score
Price MAD1,345.00
GF Value MAD1,336.11
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Other Long-Term Liabilities?

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO 90 Other Long-Term Liabilities is MAD171.5 Mil as of Dec. 2025. GuruFocus rates CAS:PRO with a GF Score™ of 90/100 and a GF Value™ of MAD1,336.11 (Fairly Valued). The stock has 6 warning signs investors should review.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's other long-term liabilities for the quarter that ended in Dec. 2025 was MAD171.5 Mil.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's quarterly other long-term liabilities increased from Dec. 2024 (MAD246.6 Mil) to Jun. 2025 (MAD262.2 Mil) but then declined from Jun. 2025 (MAD262.2 Mil) to Dec. 2025 (MAD171.5 Mil).

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's annual other long-term liabilities increased from Dec. 2023 (MAD125.8 Mil) to Dec. 2024 (MAD246.6 Mil) but then declined from Dec. 2024 (MAD246.6 Mil) to Dec. 2025 (MAD171.5 Mil).

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Other Long-Term Liabilities Related Terms

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Other Long-Term Liabilities Chart

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 68.52 125.78 246.62 171.47

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 125.78 211.96 246.62 262.21 171.47
CAS:PRO
90GF Score
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM CAS:PRO
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of MAD171.5 Mil mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Other Long-Term Liabilities of MAD171.5 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Other Long-Term Liabilities too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Other Long-Term Liabilities is MAD171.5 Mil. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Other Long-Term Liabilities compare to ZTS and UTHR?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Other Long-Term Liabilities of MAD171.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Other Long-Term Liabilities is MAD171.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,336.11, compared to a current price of MAD1,345.00 — trading 0.7% above its estimated fair value. The current Other Long-Term Liabilities is MAD171.5 Mil. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Other Long-Term Liabilities is MAD171.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?

Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued. The current stock price of MAD1,345.00 is trading 0.7% above its estimated GF Value™ of MAD1,336.11. GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.

Key valuation signals for CAS:PRO:

  • Other Long-Term Liabilities: MAD171.5 Mil
  • GF Value™: MAD1,336.11 vs. price of MAD1,345.00 (0.7% above fair value)
  • GF Score™: 90/100 with 6 warning signs

No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description

Address Rue N 7, ZI du Sahel, BP 96/97, Berrechid, Had Soualem, MAR, 26400
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
90GF Score

Get the complete analysis for CAS:PRO

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MAD1,345.00
Price
MAD1,336.11
GF Value